Double-blind placebo-controlled trial of intranasal IgE pentapeptide.
The safety and efficacy of intranasal HEPP (IgE pentapeptide) was evaluated in 30 patients with IgE-mediated allergic rhinitis. Statistically and clinically significant differences were observed in the degree of clinical improvement between HEPP and placebo groups. IgE pentapeptide 0.5% intranasal solution appears to be safe and effective in the treatment of allergic rhinitis.